Journal Article

Virologic suppression rate and associated factors for third-line HIV treatment in Addis Ababa, Ethiopia

Berhane, Abel Andargie, Awedew, Atalel Fentahun, Chimdesa, Hawibilisuma Fituma, W/Yohannes, Getachew, Bekele, Nahom Addisu, Teferi, Henok Mulatu

2024

Overview

Background HIV/AIDS has left a profound impact, leading to significant mortality, morbidity, economic strain, and disability on a global scale. The introduction of antiretroviral therapy (ART) has played a pivotal role in mitigating the economic burden of HIV and enhancing overall productivity. However, the emergence of virological failure presents a critical contemporary challenge within global health, reflecting the complexity of effectively managing HIV treatment outcomes in the 21st century. Methods An institutional based, cross-sectional study was conducted. Data were collected using a pretested, structured checklist. Data were edited and cleaned using Microsoft Excel 2016 and analyzed using SPSS version 25. Baseline demographic and clinical data were summarized using descriptive statistics. Multiple logistic regression analysis was run to identify association between dependent and independent variables, by computing odds ratio and 95% confidence interval. A p-value < 0.05 was considered significant. Results The study delved into the health profile of 117 individuals who were receiving treatment with a third-line antiretroviral therapy (ART) regimen. The findings revealed that the median age of the participants stood at 44 (IQR = ± 17) years and male accounted 53%. The median duration of after HIV diagnosis was found to be 14.25 (± IQR = 5.71) years. Overall virological suppression after third line ART was 76.9% at 6 months. Following adjustment with multiple variable logistic regression, good adherence to medication showed statistical significance in achieving virologic suppression (AOR = 8.48(95% CI: 2.3–30.8), p  = 0.001). In contrast, the absence of a change in the second line regimen (AOR = 3.0(95% CI: 0.36–24.8), p  = 0.31) and receiving second-line medication for less than three years (AOR = 1.07(95% CI: 0.39–2.95), p  = 0.89), and baseline viral load above 100,000 (AOR = 1.74(0.64–2.95), p  = 0.27) shows statistically non-significant association with virologic suppression. Clinical trial number: Not applicable. Conclusion This multicenter study provides strong evidence on virological suppression following the use of third-line antiretroviral therapy drugs in Ethiopia. The results of the study indicate rate of Virological suppression after starting third-line ART drugs is significantly linked to good adherence.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Acquired immune deficiency syndrome / Adult / AIDS / Anti-HIV Agents - therapeutic use / Antiretroviral agents / Antiretroviral drugs / Antiretroviral therapy / Antiviral agents / Confidence intervals / Cross-Sectional Studies / Data analysis / Data collection / Demographic variables / Dependent variables / Drug therapy / Drugs / Ethiopia - epidemiology / Female / Global health / HIV / HIV infection / HIV Infections - drug therapy / HIV Infections - virology / HIV long-acting treatments: profilactic and therapeutic / HIV/AIDS / Hospitals / Human immunodeficiency virus / Humans / Immune system / Independent variables / Infections / Infectious Diseases / Internal Medicine / Low income groups / Male / Median (statistics) / Medical Microbiology / Medical schools / Medicine / Medicine & Public Health / Middle Aged / Morbidity / Mortality / Observational studies / Parasitology / Patient outcomes / Patients / Population / Public health / Regression analysis / Sample size / Sampling techniques / Sociodemographics / Statistical analysis / Therapy / Third line / Treatment Outcome / Tropical Medicine / Variables / Viral Load - drug effects / Virological failure / Young Adult